Completion of enrolment in Neuren's Angelman P2 trial
Filed with ASX · · 2 pages · English
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Investor presentation, 18 December 2023
- P2 trial shows significant improvements in Phelan-McDermid
- Neuren completes enrolment in Pitt Hopkins Phase 2 trial
- DAYBUE net sales US$66.9 million in Q3 2023
- Q3 2023 quarterly activity and cash flow report
Later from Neuren Pharmaceuticals
- Q4 2023 quarterly activity report
- Q4 2023 Appendix 4C Cash Flow Report
- Comment on research report
- DAYBUE net sales US$87.1 million in Q4 2023
- Appendix 4E and 2023 full year accounts
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals